Cancer Care Gets Cheaper: NPPA Slashes Prices of 543 Medicine Brands
NPPA revises MRP for 543 anti-cancer drug brands to make treatment more affordable. New prices take effect from November 9.
In a major move to make life-saving treatment more accessible, the National Pharmaceutical Pricing Authority (NPPA) has announced a significant revision of the Maximum Retail Price (MRP) for 543 brands of anti-cancer medicine prices. Operating under the Department of Pharmaceuticals within the Ministry of Chemicals and Fertilisers, the NPPA's updated pricing list will officially come into effect on November 9.
This price revision is based on data submitted by pharmaceutical companies as of Tuesday. The authority has clarified that the list will remain dynamic, with further updates being made as manufacturers submit revised pricing for non-scheduled anti-cancer drugs.
Massive Price Drops Across Major Brands
The revised price list reveals staggering reductions in the cost of several critical medications, potentially easing the financial burden on thousands of patients. Some of the most notable price cuts include:
- Anarzole (Anastrozole 1 mg tablets): Marketed by RPG Life Sciences Ltd, the price for a pack of 10 tablets has plummeted from Rs 695.76 to just Rs 73.
- Azacytin (Azacitidine 100 mg injection): Dr. Reddy’s Laboratories Limited has seen the price of a single pack drop from Rs 6,337 to Rs 1,495.04.
- Bevacizab (Bevacizumab 100 mg/4 ml injection): Sold by Abbott Healthcare Pvt. Ltd., the MRP for a 4 ml vial has been slashed from Rs 21,767.70 to Rs 5,930.13.
- Dasanat 20 (Dasatinib 20 mg tablets): A pack of 60 tablets from Natco Pharma Limited now costs Rs 1,085.93, down from Rs 2,812.50.
Further Reductions in Specialized Treatments
RPG Life Sciences Ltd has reported further reductions for other critical drugs. Debrumab 60 mg (Denosumab 60 mg injection) in a 1 ml pre-filled syringe has seen its price drop from Rs 22,031.25 to Rs 5,941. Similarly, Enuta (Enzalutamide 40 mg capsules) in a pack of 28 has been reduced from Rs 6,578.20 to Rs 2,232.
Other significant revisions include:
- Erlib (Erlotinib 150 mg tablets): Neon Laboratories Limited reduced the price of a 30-tablet bottle from Rs 4,637.45 to Rs 2,008.
- Fludanox (Fludarabine 50 mg injection): Hetero Healthcare Ltd revised the price per vial from Rs 14,235 down to Rs 2,432.
- Fulbreca (Fulvestrant 50 mg injection): Another RPG Life Sciences product, the 5 ml vial's price dropped from Rs 26,072.16 to Rs 5,491.
The Drive for Affordability: Trade Margin Rationalisation
These price cuts follow a strategic decision made on October 17, when the NPPA announced the Trade Margin Rationalisation (TMR) for 137 non-scheduled anti-cancer drugs. This initiative was launched in the public interest to combat excessive trade margins and ensure that cancer treatment is more affordable for the average citizen.
Following this announcement, manufacturers were directed to submit revised price lists to the NPPA. The 137 targeted drugs include critical treatments such as:
- Immunotherapy medicines: Used in the treatment of more than 20 different types of cancer.
- Denosumab: Essential for patients battling prostate and breast cancer.
- Pegfilgrastim: Used to prevent neutropenia in patients undergoing cancer treatment.
- Bevacizumab: An approved treatment for cervical, ovarian, and colon cancers.